Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Carbamazepine on Darigabat PK in Healthy Adults
NCT05824143Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of darigabat in epilepsy and panic disorder, sponsored by Cerevel Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve up to the Last Specified Sampling Time and 1 more. Started Apr 2023; status: completed.
02
Drugs
darigabat
03
Conditions
epilepsypanic disorder
Beyond the preview
Go deeper on NCT05824143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824143.